Shen Zhen Weiguang Biological Products Stock Forum

The company's high P/E ratio and slower growth forecast may risk a share price decline. Investors might be overpaying for stock exposure, challenging to sustain with the earnings growth level.

Caution is advised over Weiguang Biological Products due to reliance on unusual items for profits. Risks including warning signs must be understood before investing.

Market participants may hold the company in higher regard, considering its five-year track record of earnings growth. The total shareholder return in the last 5 years, at 77%, suggests that dividends have been beneficial for shareholders.